Protara Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer and rare diseases. The company's lead investigational program is TARA-002, an intravesical cell-based immunotherapy developed from the same master cell bank as OK-432 (Picibanil). TARA-002 is currently being evaluated in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer (NMIBC) and pediatric lymphatic malformations (LMs). Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on parenteral support who are unable to meet their choline needs enterally.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing TARA-002, an investigational cell-based therapy, through registrational trials for Non-Muscle Invasive Bladder Cancer (NMIBC), focusing on completing the BCG-Unresponsive cohort of the ADVANCED-2 trial and initiating the ADVANCED-3 trial for BCG-Naïve patients.
Expected impact: Establish TARA-002 as a highly differentiated, bladder-sparing treatment option for both BCG-unresponsive and BCG-naïve NMIBC patients.
Developing TARA-002 for pediatric patients with macrocystic and mixed-cystic Lymphatic Malformations (LMs), leveraging FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.
Expected impact: Provide a novel therapeutic option for pediatric patients with LMs, addressing a significant unmet medical need in rare vascular anomalies.
Advancing the THRIVE-3 seamless Phase 2b/3 registrational clinical trial evaluating IV Choline Chloride as a phospholipid substrate replacement for patients on long-term parenteral support.
Expected impact: Address liver dysfunction and choline deficiency in patients dependent on parenteral support who cannot meet nutritional needs enterally.